Human prostate specific antigen,PSA ELISA Kit

Code CSB-E04768h
Size 96T,5×96T,10×96T
See More Details 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name kallikrein-related peptidase 3
Alternative Names antigen; prostate-specific ELISA Kit; APS ELISA Kit; Gamma seminoprotein ELISA Kit; Gamma-seminoprotein ELISA Kit; hK3 ELISA Kit; Kallikrein 3 ELISA Kit; Kallikrein related peptidase 3 ELISA Kit; Kallikrein-3 ELISA Kit; KLK 3 ELISA Kit; KLK2A1 ELISA Kit; Klk3 ELISA Kit; KLK3_HUMAN ELISA Kit; P-30 antigen ELISA Kit; P30 antigen ELISA Kit; Prostate-specific antigen ELISA Kit; Psa ELISA Kit; Semenogelase ELISA Kit; Seminin ELISA Kit
Abbreviation PSA
Uniprot No. P07288
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates
Detection Range 0.312 ng/mL-20 ng/mL
Sensitivity 0.078 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Cancer
Assay Principle quantitative
Measurement Sandwich



and FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Target Data

Function Hydrolyzes semenogelin-1 thus leading to the liquefaction of the seminal coagulum.
Gene References into Functions
  1. Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer. PMID: 28139693
  2. Men with mild to no lower urinary tract symptoms (LUTS) but increased baseline PSA are at increased risk of developing incident LUTS presumed due to benign prostatic hyperplasia PMID: 29795141
  3. PSA-density might inform biopsy decisions, and spare some men from the morbidity associated with a prostate biopsy and diagnosis of low-grade prostate cancer. PMID: 29259293
  4. Differences in fPSA-recovery between all investigated assays were even more pronounced. When applying the tPSA cutoff of 3.1 mug/L recommended for WHO-calibrated assays, the use of higher calibrated assays may lead to unnecessary prostate biopsies. Conversely, if the historical threshold of 4 mug/L is applied when using WHO-calibrated assays, it could lead to falsely omitted prostate biopsies. PMID: 29734838
  5. PSA was the only independent predictor of extensive lymph node invasion and could be an important preoperative factor for stratifying high-risk patients. PMID: 29714659
  6. ue to the biocompatibility, multivalency, stability, and high structural homogeneity, the t-PSA-specific landscape phage demonstrates as a novel specific interface in biosensors. PMID: 29414091
  7. Based on the target-induced catalytic hairpin assembly and bimetallic catalyst, the enzyme-free recycling amplification strategy for sensitive detection of prostate specific antigen (PSA) has been designed PMID: 29156407
  8. The prepared biosensor can assay from 0 to 500ng/mL of prostate specific antigen (PSA) level within 2h with the detection limit of 1.18ng/mL by the measurement of resistance change. The resistance change was caused by site selective interaction between PSA and PSA-antigen with an inexpensive bench top digital multimeter (5 1/2 digits) PMID: 29172142
  9. he superwettable f-PSA microchip can accurately detect human serum samples with excellent correlations with chemiluminescence immunoassay in the clinic, demonstrating its great potential as a sensitive and reliable sensing platform for biological analysis and clinical diagnosis. PMID: 29175217
  10. The 12-week PSA response rate was 88% (22/25) and 22% (4/18), median time to PSA progression was 18.2 months [95% confidence interval (CI), 8.3 months-not reached) and 3.7 months (95% CI, 2.8-5.6 months), and median time on treatment 21 months (range, 2.6-37.5) and 4.9 months (range, 1.3-23.2), for the AAP-naive and post-AAP cohorts, respectively. PMID: 28213364
  11. The results support that u-PSA provides useful information for predicting predicting biochemical recurrence after radical prostatectomy . This can be beneficial to avoid unnecessary adjuvant treatments or to start them earlier for selected patients PMID: 27805011
  12. this meta-analysis suggests that PSA -158G/A polymorphism may be a protecting factor against BPH in Caucasian populations, but it may enhance the disease risk in Asians. PMID: 28430620
  13. Developed risk assessment models for North Chinese patients with 4-50 ng/mL PSA to reduce unnecessary prostate biopsies and increase the detection rate of prostate cancer. PMID: 28039477
  14. Data show positive associations of relative Gal-3 and relative PSA levels in prostate cancer patients, notably at early clinical time course. PMID: 27741512
  15. Both the extent of comorbidity and the PSA doubling time should be taken into consideration when deciding on appropriate management and/or clinical trial eligibility at the time of PSA failure. PMID: 28117382
  16. As restaging in advanced prostate cancer patients is often guided by increases in PSA levels, our results demonstrate that disease progression on enzalutamide can occur without rising PSA levels. Therefore, a disease monitoring strategy that includes imaging not entirely reliant on serial serum PSA measurement may more accurately identify disease progression. PMID: 28117385
  17. Older men who underwent no PSA testing or incomplete testing were significantly more likely to be diagnosed with high-risk prostate cancer than those who were previously screened. It is reasonable to consider screening in healthy older men likely to benefit from early detection and treatment. PMID: 28045113
  18. end-of-radiation PSA was significantly associated with survival endpoints in men who received treatment with definitive radiation and ADT. Whether the EOR PSA can be used to modulate treatment intensity merits further investigation. PMID: 28094250
  19. the concentrations of insulin, IGF-1, IGFBP-3 and their association with prostate size in patients with BPH PMID: 28300542
  20. Data suggest that occurrence of PSA failure was associated with increased risk of all-cause mortality (ACM) only in men with no or minimal, but not moderate-to-severe, comorbidity. PMID: 27601545
  21. Microenvironmental acidity determines qualitatively and quantitatively the release of extracellular vesicles by malignant prostate tumors. This leads to the spill-over of nanovesicles into the peripheral blood of prostate cancer patients, where the levels of tumor biomarkers expressed by exosomes, such as PSA-exosomes, may represent a novel, non-invasive diagnostic tool. PMID: 28694142
  22. Promoter methylation of MCAM, ERalpha and ERbeta have a potential to be utilized as biomarker for the early detection of prostate cancer (PC) as their sensitivity and specificity seem to be better than serum PSA. PMID: 28147335
  23. Data suggest no influence of chronic periodontitis treatment on PSA levels in asymptomatic men. PMID: 28551659
  24. Circulating total PSA levels were strongly associated to leukocyte telomere length in a national sample of men without prostate cancer. PMID: 27566127
  25. I might also point out that whether a particular surgical procedure did more good than harm at that time was highly dependent on whether it was conducted with good sterile procedure. PSA screening is a contemporary example of this historical lesson PMID: 27010733
  26. Data show that forkhead box M1 protein (FOXM1) directly binds to the FHK binding motifs in the prostate specific antigen (PSA) promoter/enhancer regions. PMID: 28199985
  27. Study suggests that the prognostic value of PSA declines in heavily treated patients receiving enzalutamide PMID: 28614217
  28. novel urinary gene expression signature that may be the least invasive of available options by not requiring a digital rectal examination or phlebotomy as a reflex test in men for whom PSA testing raises the suspicion of prostate cancer PMID: 27031887
  29. For PSA screening to be cost-effective, it needs to be used conservatively and ideally in combination with a conservative management approach for low-risk disease PMID: 27010943
  30. Both the incidence of early-stage prostate cancer and rates of PSA screening have declined and coincide with 2012 USPSTF recommendation to omit PSA screening from routine primary care for men. Longer follow-up is needed to see whether these decreases are associated with trends in mortality. PMID: 27010657
  31. Distinctive immunohistochemical expression of PAX8 and lack of prostate-specific antigen can help in distinguishing this benign entity from prostatic adenocarcinoma. PMID: 21606823
  32. Circulating prostate-derived PSA and membrane PSM mRNA pre- and post-radical prostatectomy improves accuracy of a nomogram to predict biochemical recurrence of prostate cancer. PMID: 22228175
  33. Purified PSA cleaves complement factor iC3b in a previously uncharacterized function of PSA as an immunoregulatory serine protease that can help create an environment hospitable to malignancy through proteolysis of the complement system. PMID: 23401592
  34. Extended follow-up of the PLCO trial over a median of 15 years continues to indicate no reduction in prostate cancer mortality for the intervention arm versus the control arm. Because of the high rate of control-arm PSA testing, this finding can be viewed as showing no benefit of organized screening versus opportunistic screening PMID: 27911486
  35. Data indicate that prostate specific antigen (PSA) is a negative predictive biomarker for local recurrence during follow-up. PMID: 27834929
  36. TC genotype of rs1058205 lower in prostate cancer group than in control group; TT genotype associated with prostate cancer PMID: 28272245
  37. The prostate-specific antigen density (PSAD) cutoff level generated for Nigerian men in this study is 0.04 which is relatively different from international consensus. This PSAD cutoff level has a positive correlation with histology and could detect patients with prostate cancer who have "grey zone PSA." PMID: 27356753
  38. The combined efficacies of whole-body magnetic resonance imaging, bone scintigraphy and PSA levels were desired in identifying prostate cancer lesions and prognosis. PMID: 27941343
  39. A combination of high preoperative serum PSA and high expression of TMPRSS2-ERG could be promising in distinguishing those tumors that are aggressive and life-threatening. PMID: 27630329
  40. Higher miR-139-5p expression in prostate cancer patients was observed to be associated with certain clinicopathological parameters, including PSA greater than 20ng/ml, pathological tumor stage, and Gleason score. PMID: 27562849
  41. PSA velocity can be more predictive after surgery and PSA doubling time can be more predictive after radiation therapy. PMID: 26767890
  42. Prostate health index achieved the best predictive performance for detecting prostate cancer and was not influenced by body mass index. PMID: 26754552
  43. Salvage radiotherapy conferred better prostate cancer control when administered at the very first sign of PSA rise. PMID: 26497924
  44. Studies indicate that the prostate health index (phi) is a biomarker panel that includes free prostate-specific antigen (PSA), total PSA, and [-2]proPSA. PMID: 27023445
  45. PSCA TT genotype is associated with a more than a threefold increase in the prevalence and the extent of gastric mucosal intestinal mucosa compared to C allele carriers among H. pylori-infected Bhutanese. PMID: 26706772
  46. Prostate magnetic resonance imaging before prostate biopsy appeared to offer similar diagnostic accuracy compared with routine transrectal ultrasound-guided random biopsy in the diagnosis of suspected prostate cancer based on elevated prostate specific antigen values. PMID: 26033153
  47. We observed an association of higher Ki-67 expression with Gleason sum National Comprehensive Cancer Network risk (P=0.013) and PSA recurrence PMID: 26458958
  48. Results show that urinary PSA glycoforms are able to discriminate prostate cancer from protastatic hyperplasia with higher sensitivity and specificity for prostate cancer than those of the serum PSA marker. PMID: 27065039
  49. No significant differences in in KLK3 expression were found between radical prostatectomy-prostate cancer and radical prostatectomy-benign samples. PMID: 26928323
  50. BMI should be taken into consideration when referring men to a prostate biopsy based on serum PSA-levels. PMID: 26914149
  51. Ad5/35E1aPSESE4 is effective in marking PSA/PSMA-positive prostate cancer cells in patient blood to improve the efficacy of utilizing CTCs as a biomarker. PMID: 26723876
  52. The synthesis and serum levels of PSA are directly affected by prostate tumor cell miR-183. PMID: 25556023
  53. Prostate cancer gene 3 gene expression discriminates LN metastasis and might outperform prostate specific antigen gene activity in reflecting tumor cell burden in pelvic LNs of PCa patients. PMID: 25769446
  54. detection of prostate cancer and according to PSA screening to distinguish men with prostate cancer from men with benign prostatic hyperplasia. PMID: 26039628
  55. Of those patients who took AA with food at PSA progression, a PSA decline was observed in 3 of the 19 (16%) men, including 3 of the 14 men who had an initial response to AA (21%). PMID: 25777155
  56. Testing of four kallikrein markers in men with an elevated PSA could aid biopsy decision making in screening for lethal prostate cancer. PMID: 25682340
  57. PSA expression is highly homogenous in primary prostate cancer. PMID: 26153794
  58. The analysis based on correlation of MIC-1 and PSA concentrations in serum with the patient PCa status improved the specificity of Prostate cancer diagnosis PMID: 25853582
  59. Overexpression of the novel senescence marker GLB1 in prostate cancer predicts reduced recurrence of PSA-expressing tumors. PMID: 25876105
  60. Prediabetes is an independent determinant of high PSA levels and men with type 2 diabetes mellitus have decreased PSA levels. PMID: 25723617
  61. If validated in prospective trials, change in PSA velocity may represent a reasonable intermediate end point for screening new agents in these patients PMID: 25384338
  62. Comprehensive identification and quantitation of N-glycans from two PSA isoforms using LC-MS/MS. PMID: 25327667
  63. our results highlight the value of PSA isoforms' velocity for early detection of PCa. Especially fPSA should be used in the clinical setting to increase cancer detection specificity. PMID: 26026127
  64. MD-miniRNA was able to discriminate prostate cancer patients from prostatic hyperplasia controls with AUC of 0.79 (95 % CI 0.70-0.88). In addition, MD-miniRNA displayed a better diagnostic performance than PSA level PMID: 25557788
  65. Evaluation of PCA3 gene expression could be a reliable marker for detection of Prostate cancer,expression of this marker in urine sediments is more sensitive than blood for differentiating subjects with Prostate cancer and non-cancerous subjects. PMID: 25433473
  66. Ratio of prostate specific antigen to the outer gland volume of prostrate may be used as an indicator for the diagnosis and prognosis of prostate cancer. PMID: 25337254
  67. we focus on the susceptibilities of these PSA-PSMA prostate clones to factors that promote prostate hyperplastic, neoplastic and metastatic development PMID: 24788382
  68. Nidogen-1 is a substrate for PSA degradation. PMID: 25237904
  69. PSA isoforms were confirmed to be strong predictors of prostate cancer. PMID: 24732975
  70. The differential regulation of alternative transcripts (using KLK2, KLK3 and KLK4 as models) by androgens and anti-androgens as an indicator of prostate cancers, was investigated. PMID: 25153393
  71. Data indicate that combinations of microRNAs let-7c, miR-30c, miR-141, miR-375, and prostate-specific antigen (PSA) obtained better discrimination than PSA alone as noninvasive diagnostic biomarkers for screening of prostate cancer (PC). PMID: 25521481
  72. 303 men participated in the study of whom 113/303 (37.3%) men had prostate cancer. Of the three PSA based parameters, free percent PSA was superior, sensitivity 70.8%, and specificity 67.4% PMID: 25101294
  73. The genetic variants exhibited by PSA gene at positions -3845G/A and -158G/A may be accountable towards wide variability of serum PSA levels in prostate cancer. PMID: 24820830
  74. The [-2]pro-PSA in serum is stable for at least 24 hr at both room temperature and at 4 degrees C. PMID: 24578247
  75. the results of the present study show that the carrier frequency of four PSA-single nucleotide polymorphisms differs significantly between African-American and Caucasian men. PMID: 24712975
  76. low PSA levels may have a role in later diagnosis of prostate cancer among Japanese men PMID: 25443923
  77. Suggest that the occurrence of PCa is related to the genotype of KLK3 SNPs rs2735839. PMID: 24755043
  78. Tissue microarray of tumor sites from prostate cancer patients correlates with ERG, prostate-specific antigen (PSA), and androgen receptor (AR) expression and ERG gene rearrangement. PMID: 25043157
  79. A highly sensitive modified nucleic acid amplification assay assesses KLK3, PCA3, and TMPRSS2-ERG mRNA in castration-resistant prostate cancer patients. PMID: 25043536
  80. Extreme apical sampling of prostate-specific antigen (PSA) increases aggressive cancer detection on initial biopsy, especially in patients with standard risk of prostate cancer. PMID: 24962004
  81. PSA and neutrophil infiltrates provided a positive association in protstes diseases. PMID: 23906321
  82. Letter: report decline in PSA following cessation of abiraterone acetate therapy in metastatic castration resistant prostate cancer. PMID: 24210911
  83. Prostate-specific antigen-based prostate cancer screening can reduce the risk of dying from prostate cancer. PMID: 23954085
  84. High serum PSA levels > 100 ng/mL cis not be a prognostic factor in prostate cancer. PMID: 24747988
  85. Our study adds weight to the importance of PSA-DT and re-launches PNI as a strong prognosticator for clinically relevant endpoints. PMID: 24929427
  86. Identified prostate cancer-associated aberrant glycosylation of PSA, where alpha2,3-linked sialylation is an additional terminal N-glycan on free PSA (S2,3PSA). We then developed an assay system measuring S2,3PSA using a magnetic microbead-based immunoassay. PMID: 24814705
  87. Data indicate that prostate Cancer Gene 3 (PCA3) score was highly specific and we specially recommend its use in patients with persistent elevated prostate specific antigen (PSA) and prior negative biopsies. PMID: 22687565
  88. Predictions based on levels of four kallikrein markers, including PSA, in blood distinguish between pathologically insignificant and aggressive disease after radical prostatectomy with good accuracy. PMID: 23683475
  89. Serum IL-6 levels were compared with total PSA (tPSA), free PSA (fPSA) and the free/total ratio (f/tPSA) serum levels in prostate cancer. PMID: 24851609
  90. Alteration of cellular junctions in benign prostatic hyperplasia could contribute to the presence of luminal epithelial secreted proteins PSA and KLK2 in the stromal compartment. PMID: 24711254
  91. The aim of this study was to monitor serum levels of two microRNAs (miR-21 and miR-141) and three kallikreins (hK3/PSA, hK11, and hK13) before and 1, 5, and 30 days after radical prostatectomy. PMID: 24288670
  92. A PSA proteoform coded by SNP-L132I (rs2003783) was observed in nine samples in both heterozygous (n = 7) and homozygous (n = 2) expression profiles. PMID: 23842001
  93. Associations observed in young, healthy men between the seminal plasma and serum concentrations of hK2 and PSA and several genetic variants in KLK2 and KLK3 could be useful to refine models of PSA cutoff values in prostate cancer testing. PMID: 24270797
  94. Data indicate that induction of human prostate-specific antigen (PSA)-peptide specific specific cytotoxic T cell (CTL) responses in mice immunized with PSA-peptide and CpG-DNA were significantly greater than those of PSA-peptide only vaccination. PMID: 21982682
  95. PSA is a marker of testosterone concentrations and it may represent a new tool in confirming hypogonadism. PMID: 23859334
  96. Data indicate that although PSA density (PSAD) showed a moderate sensitivity, transabdominal ultrasound (TAUS) and transrectal ultrasound (TRUS) are the imaging modalities that calculate it closer to the real PSAD of the specimen. PMID: 22196747
  97. The increase in gene expression ratio of PSA:PSMA to about 4.95 strongly correlated with the prostate cancer and with high intratumoral angiogenesis. PMID: 24063616
  98. PSA level was mildly correlated with lower urinary tract symptom severity in benign prostatic hyperplasia. PMID: 24548953
  99. Long-term PSA velocity in addition to baseline PSA value improves classification of prostate cancer risk and mortality. PMID: 23398767
  100. High Prostate-Specific Antigen mRNA expression is associated with pelvic lymph node micrometastasis in prostate cancer. PMID: 24292502

Show More

Hide All

Subcellular Location Secreted
Protein Families Peptidase S1 family, Kallikrein subfamily
Database Links

HGNC: 6364

OMIM: 176820

KEGG: hsa:354

STRING: 9606.ENSP00000314151

UniGene: Hs.171995


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1